Stanford's ibogaine study in veterans with traumatic brain injury: what the evidence shows

The most-cited modern ibogaine study comes from Stanford Medicine. Published in Nature Medicine in January 2024, the observational study led by Dr. Nolan Williams followed 30 US Special Operations veterans with histories of repeated blast exposure and traumatic brain injury (TBI) who received ibogaine combined with intravenous magnesium at a clinic in Mexico.

Because it remains the most rigorous published dataset on ibogaine in this population, it is frequently referenced in US policy debates — including the state-level research funding discussions now shaping access in Texas and elsewhere.

Reported findings

Participants were assessed before treatment, immediately after, and one month later. On the WHO Disability Assessment Schedule, average disability scores fell from 30.2 (mild-to-moderate disability) to 5.1 (no disability) at one month.

At the one-month assessment, the authors reported average reductions of 88% in PTSD symptoms, 87% in depression symptoms and 81% in anxiety symptoms, alongside improvements in concentration, information processing and impulsivity on neuropsychological testing.

Cardiac safeguards

Ibogaine's principal risk is cardiac: it can prolong the QT interval and has been associated with dangerous arrhythmias. In the Stanford protocol, magnesium was co-administered specifically to reduce that risk, and participants underwent cardiac screening with continuous clinical supervision.

No serious adverse events or clinically significant arrhythmias were reported in the cohort. The authors were clear, however, that this does not establish general safety — the participants were screened, relatively healthy and treated in a controlled clinical setting.

Limits of the evidence

The study was open-label with no placebo or control group, involved a small and highly selected sample, and followed participants for only one month. Expectancy effects and the strong motivation of participants may have contributed to the results.

Randomized controlled trials are needed before any conclusions about efficacy can be drawn. Ibogaine remains a Schedule I substance in the United States, and no legal treatment program operates in Florida.

What it means for Miami readers

The Stanford results explain much of the renewed clinical interest in ibogaine, but they are not a basis for self-referral to unregulated providers. Anyone considering treatment abroad should insist on cardiac screening, ECG and QTc assessment, medication review and qualified medical staff — standards set out in our safety guide.

This article is educational public-health information, not medical advice. Source: Cherian KN, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 2024.